Abstract
Nonviral integrating vectors can be used for expression of therapeutic genes. piggyBac (PB), a transposon/transposase system, has been used to efficiently generate induced pluripotent stems cells from somatic cells, without genetic alteration. In this paper, we apply PB transposition to express a chimeric antigen receptor (CAR) in primary human T cells. We demonstrate that T cells electroporated to introduce the PB transposon and transposase stably express CD19-specific CAR and when cultured on CD19+ artificial antigen-presenting cells, numerically expand in a CAR-dependent manner, display a phenotype associated with both memory and effector T cell populations, and exhibit CD19-dependent killing of tumor targets. Integration of the PB transposon expressing CAR was not associated with genotoxicity, based on chromosome analysis. PB transposition for generating human T cells with redirected specificity to a desired target such as CD19 is a new genetic approach with therapeutic implications. © 2010, Mary Ann Liebert, Inc. 2010.
Cite
CITATION STYLE
Manuri, P. V. R., Wilson, M. H., Maiti, S. N., Mi, T., Singh, H., Olivares, S., … Cooper, L. J. N. (2010). PiggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Human Gene Therapy, 21(4), 427–437. https://doi.org/10.1089/hum.2009.114
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.